It also regulates the activity of key metalloproteinases, which are enzymes that promote the breakdown of extracellular matrix proteins, as well as anti-protease activity
Recent reports of reduced drinking in people being treated with glucagon-like peptide-1 receptor agonist (GLP-1RA) medications for T2DM or obesity have generated interest in the potential of these medications for treating AUD 5,6
Decreased Inflammation Fat tissue contributes to systemic inflammation
A similar pattern appeared in the STEP 4 trial, which randomized patients who had already lost weight on semaglutide to either continue treatment or switch to placebo
A dermatologist can also identify treatable causes of hair loss thyroid disease, iron deficiency, telogen effluvium and others that no peptide will address
The possibility of direct action on CSF dynamics by GLP-1 receptor activation is an area that warrants further exploration